Compare Manhattan Associates Inc (MANH) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Nuwellis Inc — how do they compare? Manhattan Associates Inc trades at $159.44 (market cap $9.79B), while Nuwellis Inc trades at $2.87 (market cap $1.09M). The key difference: Manhattan Associates Inc is far larger — about 8981.7× Nuwellis Inc's market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| MANH | NUWE | |
|---|---|---|
Market Cap | $9.79B | $1.09M |
Sector | Technology | Technology |
52-Week High | $227.94 | $527.46 |
52-Week Low | $120.88 | $2.80 |
Enterprise Value | $9.62B | -$722.58K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manhattan Associates (MANH) trades at $165.51, up 1.42% today, with a bullish technical outlook supported by moving averages and strong support at $162. The company demonstrates robust fundamentals with a 19.68% net margin and consistent earnings beats in recent quarters. Analyst sentiment remains positive with 73% buy ratings and a $192.80 consensus target, though an ongoing legal investigation has generated negative news flow.
MANH presents a growth opportunity with high profitability and earnings momentum, but faces near-term risks from legal scrutiny and premium valuations. The stock's technical strength and fundamental performance support upside potential, though investors should weigh the legal overhang against strong operational execution.
NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.
Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
